Is it safe to start tirzepatide (Zepbound) in a patient with a history of daily palpitations?

Tirzepatide (Zepbound) Can Be Started in Patients with Daily Palpitations, But Requires Careful Evaluation and Monitoring

Tirzepatide is not contraindicated in patients with palpitations and can be safely initiated after ruling out underlying arrhythmias and ensuring proper electrolyte balance, with close monitoring during dose escalation.

Clinical Approach to Starting Tirzepatide in This Patient

Pre-Treatment Evaluation Required

Before initiating tirzepatide in a patient with daily palpitations, you must:

• Obtain baseline ECG to rule out atrial fibrillation, atrial flutter, or other arrhythmias
• Check comprehensive metabolic panel including potassium, magnesium, and calcium (critical given tirzepatide's GI effects can cause electrolyte disturbances) 1
• Assess thyroid function (TSH, free T4) as tirzepatide has been associated with thyroid abnormalities including Graves' disease presenting with palpitations 2
• Evaluate for structural heart disease if palpitations are new or worsening

Evidence on Cardiac Safety

The cardiovascular safety profile of tirzepatide is reassuring for most patients:

• No significant increase in arrhythmic risk: Meta-analysis of 10,615 patients showed tirzepatide was not associated with increased atrial fibrillation (RR 1.39,95% CI 0.53-3.67) or atrial flutter (RR 1.14,95% CI 0.20-6.55) 3
• Potential benefit in AF patients: Recent data suggests tirzepatide may actually reduce AF burden in patients with type 2 diabetes and existing AF (HR 0.65,95% CI 0.55-0.76) 4
• Elevated heart rate is a known side effect: Guidelines acknowledge that GLP-1 receptor agonists and tirzepatide can cause elevated heart rate 5

Critical Safety Considerations

The main cardiac risk with tirzepatide relates to severe GI side effects causing electrolyte disturbances, not direct cardiac toxicity:

• One case report documented ventricular fibrillation and cardiac arrest in a patient on high-dose tirzepatide (15 mg) due to severe vomiting/diarrhea causing profound electrolyte depletion (K⁺ 2.2, Mg²⁺ 1.1, Ca²⁺ 5.6) 1
• Another case described new-onset atrial fibrillation requiring cardioversion shortly after starting tirzepatide 6

Practical Initiation Strategy

Start low and go slow with enhanced monitoring:

1. Begin with 2.5 mg weekly (lowest dose) rather than standard starting dose
2. Monitor electrolytes at 2 weeks and 4 weeks after initiation, then with each dose escalation
3. Counsel patient extensively on GI side effects (nausea in 25%, vomiting/diarrhea in 10%) 7
4. Instruct patient to maintain hydration and seek immediate care if severe vomiting/diarrhea occurs
5. Recheck ECG at 4-6 weeks if palpitations worsen

When to Avoid or Delay Tirzepatide

Do not start tirzepatide if:

• Palpitations are due to uncontrolled atrial fibrillation or flutter
• Patient has baseline electrolyte abnormalities
• Thyroid disease is uncontrolled or patient has personal/family history of medullary thyroid cancer 7
• Patient has severe gastroparesis or history of severe GI disease

Monitoring During Treatment

• Electrolytes: Check with each dose escalation, especially if GI symptoms develop
• Thyroid function: Recheck if palpitations worsen or new symptoms of hyperthyroidism emerge 2
• Heart rate: Document at each visit; elevated heart rate is expected but should be monitored 5
• Symptoms: Instruct patient to report worsening palpitations, dizziness (increased risk with tirzepatide, RR 1.64) 3, or syncope

Common Pitfalls to Avoid

• Escalating dose too quickly in patients with GI symptoms—this increases risk of severe electrolyte disturbances 1
• Ignoring new or worsening palpitations as "just a side effect"—always investigate for arrhythmia or thyroid dysfunction 6, 2
• Failing to counsel on hydration and electrolyte replacement during GI symptoms
• Not checking baseline thyroid function—hyperthyroidism can present with palpitations and may develop during treatment 2

Bottom Line

The evidence supports that tirzepatide does not inherently increase arrhythmic risk and may even benefit patients with existing cardiac conditions 4, 3. However, the indirect risk from severe GI side effects causing electrolyte disturbances is real and potentially life-threatening 1. With appropriate pre-treatment evaluation, slow dose titration, and vigilant electrolyte monitoring, tirzepatide can be safely used in patients with palpitations. The key is distinguishing between benign palpitations and underlying arrhythmias before starting therapy.